Trial Profile
A Double-Blind, Placebo and Active-Controlled Evaluation of the Safety and Efficacy of Cariprazine in the Acute Exacerbation of Schizophrenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs Cariprazine (Primary) ; Aripiprazole
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 18 Oct 2022 Results assessing short-term changes on quality of life and attention in schizophrenia patients treated with cariprazine, presented at the 35th Annual Congress of the European College of Neuropsychopharmacology.
- 30 Jun 2021 Results of post -hoc analysis from NCT00404573, NCT01104779, NCT00694707, NCT01104766, NCT01104792, NCT00839852, NCT01412060, EudraCT 2012-005485-36 assessing safety Profile of Cariprazine and Potential Relevance for Patient Adherence in Schizophrenia presented at the 15th World Congress of Biological Psychiatry
- 15 Sep 2020 Results of post hoc pooled analysis (NCT01104766, NCT01104779, NCT00694707) assessing efficacy of cariprazine in the early stage of schizophrenia presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology